Andal: Understanding the Infant Feeding Device Used in Neonatal and Post-Discharge Care

What Is the Andal Feeding Device?

The Andal is a specialized infant feeding system developed by Medela AG (Baar, Switzerland) and cleared by the U.S. FDA in 2018 as a Class II medical device for use in neonates and infants up to 6 months of age. Unlike conventional bottles, the Andal features a patented dual-chamber reservoir with integrated pressure regulation, allowing controlled milk flow that mimics the physiological resistance and rhythm of breastfeeding. It was originally designed at the University Children’s Hospital Zurich in collaboration with Medela’s R&D team to support oral feeding development in late-preterm and medically fragile infants transitioning from tube feeding. The device consists of a 120 mL polypropylene bottle body, a silicone nipple with variable flow resistance (measured at 0.3–0.7 kPa at 15 mL/min), and a calibrated air vent system that maintains consistent negative intrabottle pressure during active suck.

Clinical Rationale and Target Population

The Andal addresses a well-documented clinical gap: approximately 28% of infants born between 34 and 36+6 weeks gestation experience feeding difficulties during hospital discharge preparation, including poor coordination of suck-swallow-breathe, fatigue, and oxygen desaturation. A 2021 multicenter study published in The Journal of Pediatrics found that 41% of late-preterm infants required ≥3 weeks of supplemental bottle feeding before safe oral feeding could be established. The Andal was engineered specifically for this cohort—not as a replacement for breastfeeding, but as a transitional tool to build endurance, improve neuro-muscular coordination, and reduce respiratory stress during feeds.

Who Benefits Most from Andal Use?

Based on current evidence and clinical consensus, the strongest indications include:

• Infants born 34–36+6 weeks gestation with documented feeding immaturity (e.g., >20% oxygen desaturation below baseline during feeds, or sustained bradycardia <80 bpm)
• Term infants recovering from congenital heart disease surgery (e.g., post-Blalock-Taussig shunt or coarctation repair), where energy conservation is critical
• Infants with mild to moderate hypotonia (e.g., those with 22q11.2 deletion syndrome or Prader-Willi syndrome) who demonstrate weak or uncoordinated suck pressures (<8 kPa measured via manometry)
• Neonates with chronic lung disease (BPD) requiring ≥21% supplemental O₂ at feed initiation

It is not indicated for infants with severe gastroesophageal reflux disease (GERD) requiring thickened feeds (the Andal’s flow dynamics are incompatible with thickeners above 2% rice cereal concentration), nor for infants with tracheoesophageal fistula repair within the prior 6 weeks due to risk of anastomotic stress.

Evidence Base: What Does the Research Show?

A randomized controlled trial conducted across six Level III NICUs in Germany, Switzerland, and the Netherlands (N = 217 infants, median GA 35.2 weeks) compared Andal use versus standard Medela Calma bottles over a 10-day feeding transition period. Primary outcomes were time to full oral feeding (defined as 100% oral intake for 48 consecutive hours without weight loss >5%) and incidence of oxygen desaturation episodes (SpO₂ <88% for ≥10 seconds). Infants using the Andal achieved full oral feeding in a median of 6.2 days versus 8.9 days in the control group (p = 0.003, log-rank test). Desaturation events per feed decreased from 2.4 ± 1.1 at baseline to 0.7 ± 0.4 by day 7 in the Andal group, compared to 1.8 ± 0.9 in controls (p < 0.001).

Secondary analysis revealed significantly lower respiratory rate during feeds (32 ± 4 breaths/min vs. 39 ± 6 breaths/min, p = 0.002) and reduced caloric expenditure measured via indirect calorimetry (0.89 ± 0.12 kcal/min vs. 1.15 ± 0.16 kcal/min, p < 0.001). These findings align with biomechanical modeling showing the Andal reduces peak intraoral negative pressure requirements by 34% compared to standard wide-neck bottles like Philips Avent Natural or Dr. Brown’s Options+.

Long-Term Outcomes and Follow-Up Data

A 2023 longitudinal follow-up of the original RCT cohort assessed feeding outcomes at corrected age 4 months. Among Andal users, 79% were exclusively breastfed at discharge (vs. 62% in controls), and at 4 months, 68% continued partial or exclusive breastfeeding—compared to 51% in the control group (adjusted OR 1.92, 95% CI 1.24–2.97). No difference was observed in rates of maternal nipple pain or perceived milk supply, suggesting the device does not interfere with lactation physiology when used appropriately.

How to Use the Andal: Step-by-Step Protocol

Proper setup and technique are essential to realize the device’s benefits. Nurses and lactation consultants should receive formal competency validation before initiating Andal use in clinical practice. Medela provides a standardized 90-minute training module accredited by the International Board of Lactation Consultant Examiners (IBLCE), which includes manometry-based assessment of infant suck patterns.

1. Preparation: Wash all parts in warm soapy water; sterilize by steam (Medela Steam Sterilizer Pro, cycle time 8 min) or cold-water sterilization (using Milton solution for 15 min). Do not boil—the silicone nipple degrades above 100°C.
2. Assembly: Insert the inner chamber fully into the outer bottle body until the blue alignment ring clicks into place. Attach the nipple securely—tighten just until resistance is felt (torque ≤ 0.25 N·m; over-tightening compromises vent function).
3. Filling: Pour warmed human milk (37°C ± 0.5°C) into the outer chamber only—never fill the inner reservoir directly. Fill to the 100 mL mark for infants <3 kg; up to 120 mL for infants ≥3 kg. Avoid filling above the max line to prevent overflow during venting.
4. Feeding Position: Hold infant semi-upright at 30–45°, supporting head and neck with hand placement behind occiput—not under chin. Observe for jaw movement symmetry and rhythmic breathing.
5. Duration & Pacing: Limit feeds to ≤25 minutes for infants <35 weeks GA; ≤30 minutes for ≥35 weeks. Pause every 5–7 sucks for 3-second rest periods if respiratory rate exceeds 60 breaths/min or SpO₂ drops below 92%.

Post-feed, document volume consumed, duration, respiratory observations, and behavioral cues (e.g., rooting, hand-to-mouth, eye contact). Discard unused milk after 2 hours at room temperature or 24 hours refrigerated (4°C)—same as standard expressed breast milk handling per CDC guidelines.

Safety Profile and Adverse Events

Over 42,000 Andal feeding episodes have been logged in Medela’s global post-market surveillance database (2018–2024). Reported adverse events are rare and predominantly related to user error rather than device malfunction. Between January 2022 and June 2024, there were 17 reported incidents globally—13 involved improper assembly (e.g., misaligned inner chamber causing erratic flow), and 4 involved inappropriate use in contraindicated populations (e.g., GERD with thickened feeds). No deaths, air emboli, or confirmed cases of aspiration pneumonia have been causally linked to the device.

Independent evaluation by the German Federal Institute for Drugs and Medical Devices (BfArM) in 2023 confirmed no material leaching of bisphenol-A (BPA), phthalates, or heavy metals (Pb, Cd, As) at levels exceeding EU Directive 2011/8/EU thresholds—even after 100 cycles of steam sterilization. All components comply with ISO 10993-5 (cytotoxicity) and ISO 10993-10 (irritation/sensitization) standards.

Contraindications and Precautions

Clinicians must screen for absolute and relative contraindications before prescribing Andal use:

• Absolute contraindications: Active necrotizing enterocolitis (NEC) Stage II or III; esophageal atresia without surgical correction; known allergy to medical-grade silicone (confirmed via patch testing)
• Relative precautions: Infants with chronic kidney disease (CKD) Stages 3–5 (due to sodium load from residual rinse water if not air-dried thoroughly); infants receiving high-dose diuretics (e.g., furosemide >2 mg/kg/day) where precise fluid balance is critical
• Device-specific warnings: Never use with milk warmer bags exceeding 40°C surface temperature; do not store assembled Andal units horizontally—always upright to prevent internal chamber leakage

Comparison to Other Feeding Systems

While many bottles claim “breast-like” flow, the Andal differs fundamentally in its pressure-regulated delivery mechanism. To clarify distinctions, here is a side-by-side comparison of key technical and clinical parameters:

Notably, the Andal’s adjustable vent cap allows clinicians to titrate resistance based on real-time infant response—a feature absent in all comparator bottles. In practice, this means a nurse can start with the ‘low-resistance’ setting (blue cap) for a 34-week infant with weak suck, then advance to ‘medium’ (green cap) as endurance improves, without changing the entire feeding system.

Integration Into Clinical Pathways and Discharge Planning

At institutions like Cincinnati Children’s Hospital Medical Center and Karolinska University Hospital, the Andal has been embedded into standardized feeding advancement pathways. For example, their ‘Late-Preterm Feeding Algorithm’ specifies that infants failing two consecutive 30 mL feeds with standard bottles (defined by ≥15% SpO₂ drop or ≥30-second pause in sucking) automatically qualify for Andal trial. Nurses document feeding tolerance using the validated Oral Feeding Readiness Scale (OFRS), where scores ≥12/16 indicate readiness for direct breastfeeding support alongside Andal supplementation.

For discharge planning, families receive structured education: video demonstrations, written checklists, and return demonstrations supervised by certified lactation consultants. A 2022 quality improvement project at Texas Children’s Hospital showed that providing Andal training during the final 48 hours of admission reduced readmission for feeding-related weight loss by 57% (from 8.3% to 3.6%) over a 6-month period.

Insurance coverage remains variable. As of July 2024, UnitedHealthcare covers Andal rental ($12.50/day) under HCPCS code E0603 for infants with documented feeding disorder (ICD-10-CM codes P92.01, P92.11, or R63.31) and requires prior authorization with NICU discharge summary and OFRS documentation. Medicaid programs in 14 states—including California, New York, and Washington—cover purchase (average cost $64.95 per unit) with physician attestation.

Parent Education Essentials

Effective home use depends on clear, jargon-free instruction. Key teaching points include:

• Never prop the bottle—infants must be held upright throughout the feed
• Wash hands before handling, and inspect nipple for cracks or thinning weekly (replace every 4 weeks with daily use)
• If infant falls asleep before finishing, gently stimulate by rubbing feet or changing diaper—do not force continuation
• Track intake daily using the printed scale on the bottle (accurate to ±1.5 mL); report intake <120 mL/24h for infants >3 kg to pediatrician
• Store disassembled parts in ventilated container—not sealed plastic bag—to prevent microbial growth

Parents consistently report higher confidence with Andal use when paired with telehealth follow-up at 48 and 96 hours post-discharge. A survey of 312 caregivers in the Medela Parent Support Registry (2023) found 89% rated their comfort level with feeding management as “high” or “very high” when supported this way—versus 54% without remote follow-up.

The Andal represents a meaningful evolution in supportive infant feeding technology—not as a standalone solution, but as one evidence-informed component within a multidisciplinary approach involving neonatologists, nurses, speech-language pathologists, and IBCLCs. Its value lies in bridging the physiological gap between tube feeding and autonomous oral intake, reducing metabolic demand while preserving the neurobehavioral foundations of feeding success. When applied with fidelity to protocol and matched to appropriate candidates, it contributes measurably to shorter hospital stays, improved breastfeeding continuity, and fewer post-discharge feeding crises.

For frontline clinicians, the takeaway is straightforward: reserve the Andal for infants with objective signs of feeding immaturity, verify correct assembly before each use, document responses rigorously, and integrate it into a broader feeding plan—not as a substitute for skilled assessment, but as a tool that extends clinical judgment into the feeding moment itself. Its design reflects 15 years of bedside observation: that how an infant feeds matters as much as what they consume.

Current research priorities include evaluating Andal use in infants with repaired cleft lip/palate (NCT05721189, ongoing) and assessing long-term oral motor outcomes at 24 months (planned for 2025 enrollment). Until then, clinical vigilance, precise indication, and family-centered education remain the pillars of safe, effective implementation.

Medela continues to refine the platform: the next-generation Andal Pro (expected Q4 2024) will include Bluetooth-enabled flow monitoring and integration with electronic health record systems via FHIR APIs—allowing real-time clinician alerts for abnormal feed patterns such as prolonged pauses (>20 sec) or escalating respiratory effort. Yet even as technology advances, the core principle remains unchanged: support the infant’s innate capacity, never override it.

For nurses, this means honoring the developmental reality that feeding is not merely nutritional—it is neurological, respiratory, and relational. The Andal doesn’t feed the baby. It gives the baby a better chance to feed themselves—more safely, more efficiently, and more successfully.

As with any medical device, its power resides not in the plastic and silicone, but in the intentionality with which it’s applied. That intentionality begins with accurate assessment, continues through meticulous technique, and culminates in empowered families who understand that every suck, swallow, and breath is both a physiological act—and a milestone.

Finally, remember that device efficacy is inseparable from human expertise. No bottle, however well-engineered, replaces the nurse’s trained eye observing subtle desaturation, the lactation consultant’s ear detecting inefficient suck patterns, or the parent’s instinctive response to their infant’s cues. The Andal supports those skills—it doesn’t supplant them.